Who is sponsoring NCT05508815?

NCT05508815 is sponsored by Beijing University of Chinese Medicine.

What condition does NCT05508815 study?

NCT05508815 studies Arthritis, Rheumatoid.

Is NCT05508815 still recruiting?

NCT05508815 is currently status unknown. Last updated 25 May 2023.

Last reviewed 2023-05-25 · How we verify

NCT05508815

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Modified Zhiwang Decoction Combined With Methotrexate in the Treatment of Early Rheumatoid Arthritis

Status unknown EARLY_PHASE1 Last updated 25 May 2023

What this trial tests

EARLY_PHASE1 trial testing Modified Zhiwang Decoction Combined with methotrexate in Arthritis, Rheumatoid in 150 participants. Status unknown.

Timeline

9 February 2023

Primary endpoint
31 December 2024

31 December 2024

Quick facts

Lead sponsor	Beijing University of Chinese Medicine
Phase	EARLY_PHASE1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	150
Start date	9 February 2023
Primary completion	31 December 2024
Estimated completion	31 December 2024
Sites	1 location across China

Drugs / interventions tested

Modified Zhiwang Decoction Combined with methotrexate — full drug profile →
Methotrexate — full drug profile →

Conditions studied

Arthritis, Rheumatoid — all drugs for Arthritis, Rheumatoid →

Sponsor

Beijing University of Chinese Medicine

Who can join

Adults 16 to 70, any sex, with Arthritis, Rheumatoid. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to evaluate the effectiveness and safety of Modified Zhiwang Decoction in combination with methotrexate for the treatment of early RA patients and a parallel-group, single-center randomized controlled clinical study was designed.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Efficacy and safety of the modified Zhiwang decoction combined with methotrexate in early rheumatoid arthritis: study protocol for a randomised controlled trial.
Zhang N, Zhang LB, Wang Z, Lan TY, et al · · 2024 · cited 2× · PMID 38238175 · DOI 10.1136/bmjopen-2023-076571

Verify or expand the search:

Other recruiting trials for Arthritis, Rheumatoid

Currently open trials in the same condition.

NCT07176390 — A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014) · Phase 2 · recruiting
NCT06842316 — Effects of Phytocannabinoids on Immune Response and Autophagy During Chronic Immune-mediated Inflammatory Diseases · recruiting
NCT06528431 — Design and Evaluation of an Individualized Biodrug Tapering Strategy Based on Biodrug Dosage: the MONITORA Study · Phase 4 · recruiting
NCT06492200 — Impact of a High-fiber Diet on the Microbiome and Disease Activity in Patients With Rheumatoid Arthritis · NA · recruiting
NCT06246123 — A Study of Jyseleca Tablet (Filgotinib Maleate) in Korean Participants · recruiting

Other Beijing University of Chinese Medicine trials

Trials by the same sponsor.

NCT06980636 — A Trial of Shengmai Liquid for Long COVID Fatigue. · Phase 4 · recruiting
NCT07472777 — Long-term Efficacy of Modified Guilu Erxian Glue for Myasthenia Gravis · completed
NCT05941598 — Electroacupuncture for Chemotherapy-Related Cognitive Impairment · Phase 2 · unknown
NCT03759405 — IPS Differentiated Cardiomyocytes Vein Transplantation for Chronic Heart Failure · Phase 2, PHASE3 · unknown
NCT05273346 — TCM Conservative Treatment for the Degenerative Lumbar Spinal Stenosis · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05508815 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Beijing University of Chinese Medicine
Last refreshed: 25 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05508815.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing